View
3
Download
0
Category
Preview:
Citation preview
MEGA-3 FORTIFIES THE LIPID LAYERWHEN MGD PATIENTS SUFFER FROM DRY EYE.
MEGA-3 is formulated with a blend of natural oils, which protects tears from evaporating while nourishing the tear fi lm.
REF111194_v2 11/17
REFRESH OPTIVE MEGA-3®
is the only artifi cial tear that delivers a blend of fl axseed and
castor oils to the tear fi lm, in a stable nano-emulsion formula.
refreshbrand.com/docLike uson Facebook
........................................................
Destabilized Tear Film
MEGA-3 Treated Tear Film
MGD damages the lipid layer, causing tear evaporation.
Epithelial cells are desiccated due to tear hyperosmolarity.
Nano-emulsion technology delivers fl axseed and castor oil, fortifying the lipid layer and helping prevent tear evaporation without compromising patient comfort.
Polysorbate 80 keeps the nano-emulsion from separating, providing consistent stability—no shaking required.
CMC, a water-loving polymer, binds to epithelial cells to maintain moisture on the ocular surface for rapid on-eye comfort and long-lasting relief.
All OPTIVE® formulas include the patented osmoprotectant property that comes from the three compatible solutes—glycerin, l-carnitine and erythritol—all of which deliver added protection to the corneal epithelial cells against hypertonic stress.
MEGA-3 contains a fourth osmoprotectant, trehalose, for an advanced approach to treating Dry Eye symptoms.
Clinically Proven to Treat Dry Eye’s Signs and Symptoms.1
There’s a Mega Diff erence Between Our Tear Formula and Theirs.
0%
-5%
-10%
-15%
-20%
-25%
-30%
-35%
-40%
Day 7
-11% -12%
-16%
-25%-23%
-33%
-27%
-38%
Day 7Day 30 Day 30Day 60 Day 60Day 90 Day 90
Change in Combined Corneal and Conjunctival Staining by Visit
Study Days
% C
hang
e fr
om B
asel
ine
Change in OSDI by VisitStudy Days
Study design: Three-month, multicenter, double-masked, randomized study in patients with Dry Eye Disease (n = 242). Patients were assessed at baseline and at all follow-up visits (days 7, 30, 60 and 90). The primary effi cacy variable was the change from baseline in OSDI score at Day 90. The primary effi cacy analysis was
performed for the ITT population using a strategy of combined noninferiority and superiority tests. The primary effi cacy endpoint was met.1
• All patients participated in a 7 day run-in period with REFRESH PLUS.®• All patients had continuous improvement through day 90.
PRODUCT ATTRIBUTE REFRESH OPTIVE MEGA-3® SOOTHE® XP
LIPID TYPE
NANO-EMULSIONTECHNOLOGY
LUBRICANT(S)
DROPS ARE MILKY WHITEIN APPEARANCE
PRESERVATIVE-FREE
SAFE TO USE AS OFTEN AS NEEDED
Flaxseed Oil & Castor Oil
CMC, Glycerin & Polysorbate 80
NO SHAKING REQUIRED: FORMULA DOES
NOT SEPARATE
SYSTANE® BALANCE
Mineral Oil
Propylene Glycol
Light Mineral Oil & Mineral Oil
RETAINE® MGD
P L A N T - B A S E D O I L S S Y N T H E T I C O I L S
Light Mineral Oil & Mineral Oil
0%
-5%
-10%
-15%
-20%
-25%
-30%
-35%
-40%
Polysorbate 80
..................
Start selling REFRESH® in your offi ce. Call 1-833-246-4393 to get started today.
Our Complete Patented Portfolio REFRESH OPTIVE MEGA-3® joins a portfolio of patented formulas that protect epithelial cells
against hyperosmotic stress, which means immediate, long-lasting relief for your Dry Eye patients.
EVAPORATIVE DRY EYE FORMULAS
REFRESH OPTIVE® andREFRESH OPTIVE® Preservative-Free
Long-lasting Hydration Protects the surface cells of the eye
that can become damaged due to Dry Eye. REFRESH OPTIVE® Preservative-Free is
recommended for LASIK dryness.
REFRESH OPTIVE MEGA-3® Preservative-Free
Nourishes and Protects Formulated with a blend of natural oils, which protects tears from evaporation often caused by MGD while nourishing
the tear fi lm.
REFRESH OPTIVE® Gel Drops
Extended Therapy Our most comprehensive gel formula, clinically
proven to provide prolonged relief from Dry Eye symptoms,
day or night.
REFRESH OPTIVE® Advanced andREFRESH OPTIVE® Advanced Preservative-Free
Triple-action Relief Works on all three layers of the tear fi lm
and helps lubricate, hydrate and prevent tears from evaporating.
AQUEOUS-DEFICIENT DRY EYE FORMULAS
1. Data on fi le, Allergan. CSR11182X-001.© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.
Recommended